Novel approaches to retard ventricular remodeling in heart failure

European Journal of Heart Failure

Volumn 1, Issue 1, 2000, Pages 17-23

  Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heart failure; Metalloproteinases; Myocardial remodeling; Neurohormones

Indexed keywords

COLLAGEN; COLLAGENASE; COLLAGENASE 3; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PEPTIDE; PROTEIN KINASE C; SERINE PROTEINASE INHIBITOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA;

CELL SHAPE; CELL STRUCTURE; COLLAGEN DEGRADATION; CONGESTIVE HEART FAILURE; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART AFTERLOAD; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VASODILATATION;

HEART FAILURE, CONGESTIVE; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 0033086868     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(98)00012-9     Document Type: Review

References (55)

1. Howe D, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouler H. Effects of angiotensin converting enzyme on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation 1993;88:2277-2283.
2. The SOLVD investigators, Greenberg B, Quinones MA, Kollpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Circulation 1995;91:2573-2581.
3. Yang R, Bunting S, Gillett N, Clark R, Hongkui J. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995;92:262-267.
4. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. New Engl J Med 1996;334:809-814.
5. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960;5:370-382.
6. Factor SM. Role of extracellular matrix in dilated cardiomyopathy. Heart Failure 1994:260-268.
7. Robinson TF, Cohen-Gould L, Factor SM. Skeletal framework of mammalian heart muscle. Arrangement of inter- and pericellular connective tissue structures. Lab Invest 1983;49:482-498.
8. Borg TK, Terracio L. Interaction of the extracellular matrix with cardiac myocytes during development and disease. In: Robinson TF, Kinne RKH, editors. Cardiac Myocyte-connective Tissue Interactions in Health and Disease. Basel: Karger, 1990:113-130. [Stolte H, Kinne RKH, Bach PH, editors. Issues in biomedicine, vol. 13.]
9. Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers in dilated cardiomyopathy. Am Heart J 1988;116:1641-1646.
10. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: Role of metalloproteinases and pyridinoline cross links. Am J Pathol 1996;148:1639-1648.
11. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during the development and recovery from supraventricular tachycardia. Am J Physiol 1991;261:H308-H318.
12. Janicki JS, Matsubara BB. Myocardial collagen and left ventricular diastolic dysfunction. In: Gaash WH, LeWinter MM, editors. Left Ventricular Diastolic Dysfunction and Heart Failure. Lea and Febiger, 1994:125-140.
13. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim AE, Powell JR, Koster WH. Angiotensin converting enzyme inhibition and the progression of congestive cardiomyopathy: Effects on left ventricular and myocyte structure and function. Circulation 1995;92:562-568.
14. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function. Circul Res 1998;82:482-495.
15. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-1715.
16. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin system. Circulation 1991;83:1849-1865.
17. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of Rheumatology. New York: WB Saunders, 1993:248-268.
18. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996;148:1345-1350.
19. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
20. Hansen-Birkedal H, Moore WGI, Bodden MK, Windsor LJ, Hansen-Birkedal B, DeCarlo A, Engler JA. Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 1993;4:197-250.
21. Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS. The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth. Int J Obes 1996;20:S9-S15.
22. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
23. Coker ML, Thomas CV, Doscher MA, Galis ZS, Spinale FG. Matrix metalloproteinase expression and activity in adult ventricular myocytes: Influence of basement membrane adhesion. Circulation (I-689; Abstract), 1997.
24. Brenner DA, O'Hara M, Angel P, Chojkler M, Karin M. Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha. Nature 1989;337:661-663.
25. Shonthal A, Herrlich P, Rahmsdorf HJ, Ponta H. Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell 1988;54:325-334.
26. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem 1995;376:345-355.
27. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New Engl J Med 1990;223:236-241.
28. Kerr LD, Miller DB, Matrisian LM. TGF-beta 1 inhibition of transin/stromelysin gene expression is mediated through Fos binding sequences. Cell 1990;61:267-278.
29. Saito Y., Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
30. Frisch SM, Morisaki JH. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol Cell Biol 1990;10:6524-6532.
31. Nagase H. Activational mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
32. 73 active site zine complex in latency and a 'cysteine switch' mechanism for activation. Proc Natl Acad Sci USA 1990;87:364-368.
33. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-2636.
34. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of the matrix metalloproteinase 3 (stromelysin) by proteinases and mercuric acetate. Biochemistry 1990;29:5783-5789.
35. Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. J Biol Chem 1985;260:12367-12376.
36. Werb Z, Hembry RM, Murphy G, Aggeler J. Commitment to expression of the metalloendopeptidases, collagenase and stromelysin: Relationship of inducing events to changes in cytoskeletal architecture. J Cell Biol 1986;102:697-702.
37. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. Biochem J 1987;248:265-268.
38. Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler-Stevenson WG, Seiki M. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT-MMP). FEBS Lett 1996; 385:238-240.
39. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65.
40. Pei D, Weiss SJ. Furin dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244-247.
41. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in failing human heart. Circulation 1998;98:1728-1734.
42. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloprotease designated TIMP. Proc Natl Acad Sci USA 1989;86:8207-8211.
43. Silbiger SM, Jacobsen VL, Cupples RL, Koski RA. Cloning of cDNAs encoding human TIMP-3, a novel member of the tissue inhibitor of metalloproteinase family. Gene 1994;141:293-297.
44. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metallproteinases-3 (TIMP-3 is an extracellular matrix associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269:9352-9360.
45. Green J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metallproteinase 4. J Biol Chem 1996;271:30375-30380.
46. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
47. Brophy CM, Marks WH, Reilly JM, Tilson MD. Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: A preliminary report. J Surg Res 1991;50:653-657.
48. Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J 1996;315:335-342.
49. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitor (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145-149.
50. Butler GS, Will H, Atkinson SJ, Murphy G. Membrane type 2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem 1997;244:653-657.
51. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-4728.
52. Hodgson J. Remodeling MMPIs. Biotechnology 1995;13:554-557.
53. Spinale FG, Krombach RS, Coker ML, Mukherjee R, Houck WV, Clair MJ, Kribbs SB, Hebbar L. Matrix metalloproteinase inhibition with congestive heart failure improves left ventricular geometry and pump function. Seventieth Scientific Session of the American Heart Association, November 1997.
54. Hua L, Dillon L, Bocan TMA, Peterson T. MMP upregulation in the myocardial infarcted rat and the effect of MMP inhibitor treatment with PD166793. Seventy-First Scientific Session of the American Heart Association, November 1998.
55. Mack CA, Patel SR, Schwarz EA et al. Biological bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998;115:168-177.